Novo Nordisk (NVO) slides as GLP-1 pricing and competition worries stay in focus

Novo Nordisk (NVO) is down 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued investor concern that intensifying obesity-drug competition and U.S. pricing pressure will weigh on Novo Nordisk’s growth and margins. Recent developments around price concessions and new oral competitors have kept sentiment fragile, so the stock can react sharply even without a single, new headline.

Details:

Novo Nordisk disclosed plans to reduce U.S. list prices for key semaglutide brands effective January 1, 2027, reinforcing expectations for a tougher pricing environment ahead.

A newly approved rival weight-loss pill in the U.S. has raised expectations that competition will shift toward more convenient oral options, potentially pressuring demand and net pricing across the category.

The company has recently communicated a weaker 2026 outlook than investors had been accustomed to, keeping the market sensitive to any incremental signals on demand, share, and profitability.

Investors may also be digesting updated risk disclosures and business commentary in the company’s freshly published annual reporting materials.

Sources:

Novo Nordisk (press release; annual reporting materials), Associated Press, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NVO Hedge Fund Activity

We have seen 569 institutional investors add shares of $NVO stock to their portfolio, and 773 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398
FAYEZ SAROFIM & CO removed 3,118,838 shares (-42.4%) from their portfolio in Q4 2025, for an estimated $158,686,477
DAVENPORT & CO LLC removed 2,122,035 shares (-96.2%) from their portfolio in Q1 2026, for an estimated $76,085,564

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$NVO Congressional Stock Trading

Members of Congress have traded $NVO stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$NVO Analyst Ratings

Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Goldman Sachs issued a "Buy" rating on 11/28/2025
Jefferies issued a "Underperform" rating on 10/27/2025

To track analyst ratings and price targets for $NVO, check out Quiver Quantitative's $NVO forecast page.

$NVO Price Targets

Multiple analysts have issued price targets for $NVO recently. We have seen 3 analysts offer price targets for $NVO in the last 6 months, with a median target of $46.0.

Here are some recent targets:

James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
An analyst from CICC set a target price of $73.5 on 01/09/2026
Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.